Phospholamban pentamerization increases sensitivity and dynamic range of cardiac relaxation

Abstract Aims A key event in the regulation of cardiac contraction and relaxation is the phosphorylation of phospholamban (PLN) that relieves the inhibition of the sarco/endoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a). PLN exists in an equilibrium between monomers and pentamers. While only monomers can inhibit SERCA2a by direct interaction, the functional role of pentamers is still unclear. This study investigates the functional consequences of PLN pentamerization. Methods and results We generated transgenic mouse models expressing either a PLN mutant that cannot form pentamers (TgAFA-PLN) or wild-type PLN (TgPLN) in a PLN-deficient background. TgAFA-PLN hearts demonstrated three-fold stronger phosphorylation of monomeric PLN, accelerated Ca2+ cycling of cardiomyocytes, and enhanced contraction and relaxation of sarcomeres and whole hearts in vivo. All of these effects were observed under baseline conditions and abrogated upon inhibition of protein kinase A (PKA). Mechanistically, far western kinase assays revealed that PLN pentamers are phosphorylated by PKA directly and independent of any subunit exchange for free monomers. In vitro phosphorylation of synthetic PLN demonstrated that pentamers even provide a preferred PKA substrate and compete with monomers for the kinase, thereby reducing monomer phosphorylation and maximizing SERCA2a inhibition. However, β-adrenergic stimulation induced strong PLN monomer phosphorylation in TgPLN hearts and sharp acceleration of cardiomyocyte Ca2+ cycling and haemodynamic values that now were indistinguishable from TgAFA-PLN and PLN-KO hearts. The pathophysiological relevance of PLN pentamerization was evaluated using transverse aortic constriction (TAC) to induce left ventricular pressure overload. Compared to TgPLN, TgAFA-PLN mice demonstrated reduced survival after TAC, impaired cardiac haemodynamics, failure to respond to adrenergic stimulation, higher heart weight, and increased myocardial fibrosis. Conclusions The findings show that PLN pentamerization greatly impacts on SERCA2a activity as it mediates the full range of PLN effects from maximum inhibition to full release of SERCA2a function. This regulation is important for myocardial adaptation to sustained pressure overload.

[1]  K. Hansson,et al.  Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy , 2021, Nature Communications.

[2]  M. J. Lemieux,et al.  Dwarf open reading frame (DWORF) is a direct activator of the sarcoplasmic reticulum calcium pump SERCA , 2021, eLife.

[3]  J. Schmitt,et al.  Molecular Noise-Filtering in the β-adrenergic Signaling Network by Phospholamban Pentamers , 2020, bioRxiv.

[4]  C. Ottmann,et al.  14-3-3 binding creates a memory of kinase action by stabilizing the modified state of phospholamban , 2020, Science Signaling.

[5]  S. Hauptmann,et al.  Alterations of protein expression of phospholamban, ZASP and plakoglobin in human atria in subgroups of seniors , 2019, Scientific Reports.

[6]  M. J. Lemieux,et al.  The Phospholamban Pentamer Alters Function of the Sarcoplasmic Reticulum Calcium Pump SERCA. , 2019, Biophysical journal.

[7]  Akshay S. Desai,et al.  Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial , 2016, The Lancet.

[8]  V. Anderson.  Multiple alternative substrate kinetics. , 2015, Biochimica et biophysica acta.

[9]  J. Schmitt,et al.  Cardiac RKIP induces a beneficial β-adrenoceptor–dependent positive inotropy , 2015, Nature Medicine.

[10]  J. Schmitt,et al.  Phospholamban pentamers attenuate PKA-dependent phosphorylation of monomers. , 2015, Journal of molecular and cellular cardiology.

[11]  J. Schmitt,et al.  &bgr;-Myosin Heavy Chain Variant Val606Met Causes Very Mild Hypertrophic Cardiomyopathy in Mice, but Exacerbates HCM Phenotypes in Mice Carrying Other HCM Mutations , 2014, Circulation research.

[12]  K. Zsebo,et al.  Long-Term Effects of AAV1/SERCA2a Gene Transfer in Patients With Severe Heart Failure: Analysis of Recurrent Cardiovascular Events and Mortality , 2014, Circulation research.

[13]  G. Veglia,et al.  Allosteric regulation of SERCA by phosphorylation-mediated conformational shift of phospholamban , 2013, Proceedings of the National Academy of Sciences.

[14]  A. Trafford,et al.  Sarcoplasmic Reticulum Ca-ATPase and Heart Failure 20 Years Later , 2013, Circulation research.

[15]  T. Hurley,et al.  The Structural Basis for Phospholamban Inhibition of the Calcium Pump in Sarcoplasmic Reticulum* , 2013, The Journal of Biological Chemistry.

[16]  R. Hajjar,et al.  Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy , 2012, Nature Reviews Cardiology.

[17]  C. Holmes,et al.  Lethal, Hereditary Mutants of Phospholamban Elude Phosphorylation by Protein Kinase A* , 2012, The Journal of Biological Chemistry.

[18]  Tracy J. Pritchard,et al.  The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase. , 2012, Journal of molecular and cellular cardiology.

[19]  Barry Greenberg,et al.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure , 2011, Circulation.

[20]  G. Veglia,et al.  Structural topology of phospholamban pentamer in lipid bilayers by a hybrid solution and solid-state NMR method , 2011, Proceedings of the National Academy of Sciences.

[21]  L. Masterson,et al.  Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A , 2011, Proceedings of the National Academy of Sciences.

[22]  D. Stokes,et al.  Phosphorylation and mutation of phospholamban alter physical interactions with the sarcoplasmic reticulum calcium pump. , 2011, Journal of molecular biology.

[23]  K. Jones,et al.  Inducible Expression of Active Protein Phosphatase-1 Inhibitor-1 Enhances Basal Cardiac Function and Protects Against Ischemia/Reperfusion Injury , 2009, Circulation research.

[24]  V. Erdmann,et al.  Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy , 2009, Circulation.

[25]  R. Hajjar,et al.  Rescue of Ca2+ overload-induced left ventricular dysfunction by targeted ablation of phospholamban. , 2009, American journal of physiology. Heart and circulatory physiology.

[26]  Ferhaan Ahmad,et al.  Alterations of Phospholamban Function Can Exhibit Cardiotoxic Effects Independent of Excessive Sarcoplasmic Reticulum Ca2+-ATPase Inhibition , 2009, Circulation.

[27]  Z. Hou,et al.  Phosphomimetic Mutations Increase Phospholamban Oligomerization and Alter the Structure of Its Regulatory Complex* , 2008, Journal of Biological Chemistry.

[28]  Yuliang Wu,et al.  Detecting protein–protein interactions by far western blotting , 2007, Nature Protocols.

[29]  K. Campbell,et al.  Förster Transfer Recovery Reveals That Phospholamban Exchanges Slowly From Pentamers but Rapidly From the SERCA Regulatory Complex , 2007, Circulation research.

[30]  I. Sjaastad,et al.  Increased cardiomyocyte function and Ca2+ transients in mice during early congestive heart failure. , 2007, Journal of molecular and cellular cardiology.

[31]  K. Chien,et al.  Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. , 2007, Journal of the American College of Cardiology.

[32]  D. Stokes,et al.  Interactions between Ca2+-ATPase and the pentameric form of phospholamban in two-dimensional co-crystals. , 2006, Biophysical journal.

[33]  G. Dorn,et al.  A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[34]  E. Kranias,et al.  Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions. , 2005, Cardiovascular research.

[35]  J. Ross,et al.  Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. , 2005, Cardiovascular research.

[36]  Richard T. Lee,et al.  Consequences of Pressure Overload on Sarcomere Protein Mutation-Induced Hypertrophic Cardiomyopathy , 2003, Circulation.

[37]  E. Kranias,et al.  Calcium: Phospholamban: a crucial regulator of cardiac contractility , 2003, Nature Reviews Molecular Cell Biology.

[38]  C. Heizmann,et al.  Ca2+ -dependent interaction of S100A1 with the sarcoplasmic reticulum Ca2+ -ATPase2a and phospholamban in the human heart. , 2003, Biochemical and biophysical research communications.

[39]  Ulrike Mende,et al.  Dilated Cardiomyopathy and Heart Failure Caused by a Mutation in Phospholamban , 2003, Science.

[40]  D. Maclennan,et al.  Sarcolipin Inhibits Polymerization of Phospholamban to Induce Superinhibition of Sarco(endo)plasmic Reticulum Ca2+-ATPases (SERCAs)* , 2002, The Journal of Biological Chemistry.

[41]  Harvard Medical School,et al.  Targeting Phospholamban by Gene Transfer in Human Heart Failure , 2002, Circulation.

[42]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[43]  D. D. Thomas,et al.  Synthetic null-cysteine phospholamban analogue and the corresponding transmembrane domain inhibit the Ca-ATPase. , 2000, Biochemistry.

[44]  D M Bers,et al.  Calcium fluxes involved in control of cardiac myocyte contraction. , 2000, Circulation research.

[45]  B. Hoit,et al.  The Transgenic Expression of Highly Inhibitory Monomeric Forms of Phospholamban in Mouse Heart Impairs Cardiac Contractility* , 2000, The Journal of Biological Chemistry.

[46]  D. D. Thomas,et al.  Depolymerization of phospholamban in the presence of calcium pump: a fluorescence energy transfer study. , 1999, Biochemistry.

[47]  D. Bers,et al.  Pentameric Assembly of Phospholamban Facilitates Inhibition of Cardiac Function in Vivo * , 1998, The Journal of Biological Chemistry.

[48]  L. Jones,et al.  Functional Co-expression of the Canine Cardiac Ca2+Pump and Phospholamban in Spodoptera frugiperda (Sf21) Cells Reveals New Insights on ATPase Regulation* , 1997, The Journal of Biological Chemistry.

[49]  D. Maclennan,et al.  Phospholamban Inhibitory Function Is Activated by Depolymerization* , 1997, The Journal of Biological Chemistry.

[50]  D. D. Thomas,et al.  Mutation and phosphorylation change the oligomeric structure of phospholamban in lipid bilayers. , 1997, Biochemistry.

[51]  J. Colyer,et al.  Translation of Ser16 and Thr17 phosphorylation of phospholamban into Ca 2+-pump stimulation. , 1996, The Biochemical journal.

[52]  Yvonne M. Kobayashi,et al.  A Leucine Zipper Stabilizes the Pentameric Membrane Domain of Phospholamban and Forms a Coiled-coil Pore Structure (*) , 1996, The Journal of Biological Chemistry.

[53]  R. Walsh,et al.  Differential changes in cardiac phospholamban and sarcoplasmic reticular Ca(2+)-ATPase protein levels. Effects on Ca2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. , 1995, Circulation research.

[54]  T. Doetschman,et al.  Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. , 1994, Circulation research.

[55]  W. Rutter,et al.  Analysis of enzyme specificity by multiple substrate kinetics. , 1993, Biochemistry.

[56]  J. H. Wang,et al.  Immunological detection of phospholamban phosphorylation states facilitates the description of the mechanism of phosphorylation and dephosphorylation. , 1990, Biochemistry.

[57]  J. Schmitt,et al.  A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy , 2009, Nature Medicine.

[58]  T. Toyofuku,et al.  Sites of regulatory interaction between calcium ATPases and phospholamban , 2004, Basic Research in Cardiology.

[59]  M. Jiang,et al.  Age-related alterations in the phosphorylation of sarcoplasmic reticulum and myofibrillar proteins and diminished contractile response to isoproterenol in intact rat ventricle. , 1993, Circulation research.